Evidence digest
What the research on Sermorelin actually shows
The indexed literature on Sermorelin includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Sermorelin is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
Updated 25 Aug 2026 · 4 studies indexed · 4 human · compound record
- Studies indexed
- 4
- Human evidence
- 4
- Preclinical only
- 0
What is and is not established
What the literature supports
- Human clinical or observational records are indexed for Sermorelin (4).
- Published research is indexed back to 1984, with roughly 331 PubMed records located.
- It is listed by one or more vendors tracked in this index.
What is NOT established
- This index does not evaluate whether Sermorelin is safe or effective for any use.
- Material sold by the vendors indexed here is labeled for laboratory research use only and is not a regulator-approved medicine in that form.
- No dosing, protocol or human-use guidance is provided or implied anywhere in this index.
Studies indexed
3 human — controlled trial · 1 case report
| Study | Evidence type | Model | n | What it reported | Source |
|---|---|---|---|---|---|
| Quantitative growth hormone secretion and final adult heightClinical endocrinology · 1999 | Human — controlled trial | Not recorded | — | The relationship of quantitative GH secretion to height, growth velocity and puberty is complex and has been the subject of extensive study in children. This study was designed to relate quantitative GH secretion to final height. Twenty tall (> 183 cm, 90th centile for adult height) and 20 short (< 166 cm, 10th centile) postpubertal men who had recently completed linear growth (age range 18-27 years). GH dynamics were studied on four occasions; insulin (0.15 units/kg, iv)-ind… | PMID 10594520 |
| Anterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case reportFrontiers in surgery · 2026 | Case report | Not recorded | — | Anterior cervical osteophytes can compress the esophagus, producing dysphagia. Although common on imaging in older adults, symptomatic osteophytic dysphagia is underdiagnosed, and the role of systemic anabolic factors in osteophyte growth is poorly characterized. A 62-year-old male ex-military recreational bodybuilder presented with cervicalgia and left shoulder pain. Cervical radiographs and MRI demonstrated multilevel degenerative changes including a prominent anterior oste… | PMID 42465868 |
| Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormoneActa paediatrica (Oslo, Norway : 1992). Supplement · 1993 | Human — controlled trial | Not recorded | — | To assess the growth-promoting effect of different doses of growth hormone-releasing hormone(1-29)-NH2 (GHRH(1-29)-NH2) in GH deficiency (GHD) of hypothalamic origin, 43 prepubertal children aged between 4.3 and 18.9 years (mean 10.4 +/- 2.9 years) were randomly assigned to three treatment regimens: low-dose GHRH(1-29)-NH2 (LD group; n = 15), high-dose GHRH(1-29)-NH2 (HD group; n = 12) and GH (GH group; n = 16). The LD group received GHRH(1-29)-NH2 at 30 micrograms/kg/day s.c… | PMID 8329826 |
| Growth hormone release by the novel GH releasing peptide hexarelin in patients with homozygous beta-thalassemiaJournal of pediatric endocrinology & metabolism : JPEM · 1997 | Human — controlled trial | Not recorded | — | Patients with beta-thalassemia often present with abnormalities in growth and other endocrine functions. Growth hormone (GH) secretion is controlled via somatostatin and growth hormone releasing hormone (GHRH). Recently, Hexarelin, a new potent GH secretagogue (His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH2), was synthesized. Our study was designed to assess and compare its efficacy as a GH secretagogue to GHRH 1-29 in beta-thalassemia. Eighteen patients, regularly transfused and c… | PMID 9364340 |
Vendors listing Sermorelin
The evidence above describes the published literature. What any individual vial contains is a separate question, answered by that vendor’s certificate records rather than by any study on this page.
| Vendor | Score · Coverage | Certificates | |
|---|---|---|---|
| Polaris Peptides | 93.877% | 1 | profile → |
| Next Gen Peptides | 93.897% | 2 | profile → |
| Ascend Science | 90.291% | 1 | profile → |
| PeptidePlugs | 89.790% | 1 | profile → |
| Protide Health | 83.994% | 0 | profile → |
| American Peptides | 83.6100% | 1 | profile → |
| Northline Labs | 79.493% | 1 | profile → |
| Koi Peptides | 79.394% | 1 | profile → |
| Good Science Bio | 79.275% | 0 | profile → |
| Ascension Peptides | 78.186% | 1 | profile → |
| Licensed Peptides | 7789% | 1 | profile → |
| Simple Peptide | 7489% | 1 | profile → |
| Eternal Peptides | 68.265% | 0 | profile → |
| Evolve Peptides | 65.567% | 0 | profile → |
| Mile High Compounds | 65.494% | 0 | profile → |
| Sports Technology Labs | 56.174% | 0 | profile → |
How to read this page
This digest describes what published research exists and what it does not establish. It is not a recommendation, contains no dosing information or protocols, and makes no claim that any compound is safe or effective for any purpose. Material listed by indexed vendors is labeled for laboratory research use only.